Загрузка...
mTOR inhibitors in renal cell carcinoma
The mammalian target of rapamycin (mTOR) is a downstream effector of the PI3-K/Akt/mTOR pathway. Allosteric inhibitors of mTOR, everolimus and temsirolimus, have shown promising clinical activity in advanced renal cell carcinoma but their effect is far from durable and only a subset of patients expe...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2011
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3164983/ https://ncbi.nlm.nih.gov/pubmed/21894244 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/thy.11.32 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|